

## **Hospital Infection Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028**

Market Report | 2023-10-15 | 142 pages | IMARC Group

### **AVAILABLE LICENSES:**

- Electronic (PDF) Single User \$2499.00
- Five User Licence \$3499.00
- Enterprisewide License \$4499.00

### **Report description:**

Market Overview:

The global hospital infection therapeutics market size reached US\$ 11.8 Billion in 2022. Looking forward, IMARC Group expects the market to reach US\$ 15.8 Billion by 2028, exhibiting a growth rate (CAGR) of 4.8% during 2023-2028.

Hospital infection therapeutics refers to various pharmaceutical drugs used for the treatment of nosocomial infections. These infections can be acquired at hospitals, nursing homes, rehabilitation facilities and other clinical settings and are usually treated by antiviral, antibacterial and antifungal medicines. The antibacterial therapeutics consist of cell wall synthesis and protein synthesis inhibitors, such as vancomycin, carbapenems, cephalosporins, linezolid, aminoglycosides and tigecycline. The antifungal therapeutics include caspofungin and Amphotericin B. These drugs aid in preventing the instances of hospital-acquired pneumonia, urinary tract infections (UTIs), gastrointestinal disorders, bloodstream infections and surgical site infections.

The increasing prevalence of hospital-acquired diseases (HAD) is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. Resulting from the deterioration of hygiene facilities in hospitals and other healthcare institutions, there has been a significant increase in the occurrence of hospital-acquired pneumonia and other infections, which is contributing to the increasing demand for hospital infection therapeutics. Additionally, various product innovations, such as the development of advanced microbial wound care drugs, coverings and vaccines, are acting as other growth-inducing factors. Product manufacturers are developing antimicrobial drugs and pipeline drug molecules that are effective against multi-drug resistant infections and can be used for the treatment of infections with specific symptoms. Other factors, including extensive research and development (R&D) activities, along with improvements in the healthcare infrastructure, are expected to drive the market further.

Key Market Segmentation:

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

IMARC Group provides an analysis of the key trends in each sub-segment of the global hospital infection therapeutics market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on drug type and indication.

Breakup by Drug Type:

- Anti-bacterial Drugs
- Anti-fungal Drugs
- Anti-viral Drugs
- Others

Breakup by Indication:

- Blood Stream Infections
- Urinary Tract Infections
- Surgical Site Infections
- Pneumonia
- Others

Breakup by Region:

- North America
  - United States
  - Canada
- Asia Pacific
  - China
  - Japan
  - India
  - South Korea
  - Australia
  - Indonesia
  - Others
- Europe
  - Germany
  - France
  - United Kingdom
  - Italy
  - Spain
  - Russia
  - Others
- Latin America
  - Brazil
  - Mexico
  - Others
- Middle East and Africa

Competitive Landscape:

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

The report has also analysed the competitive landscape of the market with some of the key players being Allergan Plc (AbbVie Inc.), AstraZeneca Plc, Bayer Aktiengesellschaft, Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc, Pfizer Inc. and Sanofi S.A.

#### Key Questions Answered in This Report:

How has the global hospital infection therapeutics market performed so far and how will it perform in the coming years?

What has been the impact of COVID-19 on the global hospital infection therapeutics market?

What are the key regional markets?

What is the breakup of the market based on the drug type?

What is the breakup of the market based on the indication?

What are the various stages in the value chain of the industry?

What are the key driving factors and challenges in the industry?

What is the structure of the global hospital infection therapeutics market and who are the key players?

What is the degree of competition in the industry?

#### Table of Contents:

1	Preface
2	Scope and Methodology
2.1	Objectives of the Study
2.2	Stakeholders
2.3	Data Sources
2.3.1	Primary Sources
2.3.2	Secondary Sources
2.4	Market Estimation
2.4.1	Bottom-Up Approach
2.4.2	Top-Down Approach
2.5	Forecasting Methodology
3	Executive Summary
4	Introduction
4.1	Overview
4.2	Key Industry Trends
5	Global Hospital Infection Therapeutics Market
5.1	Market Overview
5.2	Market Performance
5.3	Impact of COVID-19
5.4	Market Forecast
6	Market Breakup by Drug Type
6.1	Anti-bacterial Drugs
6.1.1	Market Trends
6.1.2	Market Forecast
6.2	Anti-fungal Drugs
6.2.1	Market Trends
6.2.2	Market Forecast
6.3	Anti-viral Drugs
6.3.1	Market Trends
6.3.2	Market Forecast
6.4	Others

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 7 Market Breakup by Indication
- 7.1 Blood Stream Infections
  - 7.1.1 Market Trends
  - 7.1.2 Market Forecast
- 7.2 Urinary Tract Infections
  - 7.2.1 Market Trends
  - 7.2.2 Market Forecast
- 7.3 Surgical Site Infections
  - 7.3.1 Market Trends
  - 7.3.2 Market Forecast
- 7.4 Pneumonia
  - 7.4.1 Market Trends
  - 7.4.2 Market Forecast
- 7.5 Others
  - 7.5.1 Market Trends
  - 7.5.2 Market Forecast
- 8 Market Breakup by Region
- 8.1 North America
  - 8.1.1 United States
    - 8.1.1.1 Market Trends
    - 8.1.1.2 Market Forecast
  - 8.1.2 Canada
    - 8.1.2.1 Market Trends
    - 8.1.2.2 Market Forecast
- 8.2 Asia Pacific
  - 8.2.1 China
    - 8.2.1.1 Market Trends
    - 8.2.1.2 Market Forecast
  - 8.2.2 Japan
    - 8.2.2.1 Market Trends
    - 8.2.2.2 Market Forecast
  - 8.2.3 India
    - 8.2.3.1 Market Trends
    - 8.2.3.2 Market Forecast
  - 8.2.4 South Korea
    - 8.2.4.1 Market Trends
    - 8.2.4.2 Market Forecast
  - 8.2.5 Australia
    - 8.2.5.1 Market Trends
    - 8.2.5.2 Market Forecast
  - 8.2.6 Indonesia
    - 8.2.6.1 Market Trends
    - 8.2.6.2 Market Forecast
  - 8.2.7 Others
    - 8.2.7.1 Market Trends

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 8.2.7.2 Market Forecast
- 8.3 Europe
  - 8.3.1 Germany
    - 8.3.1.1 Market Trends
    - 8.3.1.2 Market Forecast
  - 8.3.2 France
    - 8.3.2.1 Market Trends
    - 8.3.2.2 Market Forecast
  - 8.3.3 United Kingdom
    - 8.3.3.1 Market Trends
    - 8.3.3.2 Market Forecast
  - 8.3.4 Italy
    - 8.3.4.1 Market Trends
    - 8.3.4.2 Market Forecast
  - 8.3.5 Spain
    - 8.3.5.1 Market Trends
    - 8.3.5.2 Market Forecast
  - 8.3.6 Russia
    - 8.3.6.1 Market Trends
    - 8.3.6.2 Market Forecast
  - 8.3.7 Others
    - 8.3.7.1 Market Trends
    - 8.3.7.2 Market Forecast
- 8.4 Latin America
  - 8.4.1 Brazil
    - 8.4.1.1 Market Trends
    - 8.4.1.2 Market Forecast
  - 8.4.2 Mexico
    - 8.4.2.1 Market Trends
    - 8.4.2.2 Market Forecast
  - 8.4.3 Others
    - 8.4.3.1 Market Trends
    - 8.4.3.2 Market Forecast
- 8.5 Middle East and Africa
  - 8.5.1 Market Trends
  - 8.5.2 Market Breakup by Country
  - 8.5.3 Market Forecast
- 9 SWOT Analysis
  - 9.1 Overview
  - 9.2 Strengths
  - 9.3 Weaknesses
  - 9.4 Opportunities
  - 9.5 Threats
- 10 Value Chain Analysis
- 11 Porters Five Forces Analysis
  - 11.1 Overview
  - 11.2 Bargaining Power of Buyers

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 11.3Bargaining Power of Suppliers
- 11.4Degree of Competition
- 11.5Threat of New Entrants
- 11.6Threat of Substitutes
- 12 Price Analysis
- 13 Competitive Landscape
- 13.1Market Structure
- 13.2Key Players
- 13.3Profiles of Key Players
  - 13.3.1Allergan Plc (AbbVie Inc.)
    - 13.3.1.1 Company Overview
    - 13.3.1.2 Product Portfolio
    - 13.3.1.3 Financials
    - 13.3.1.4 SWOT Analysis
  - 13.3.2AstraZeneca Plc
    - 13.3.2.1 Company Overview
    - 13.3.2.2 Product Portfolio
    - 13.3.2.3 Financials
    - 13.3.2.4 SWOT Analysis
  - 13.3.3Bayer Aktiengesellschaft
    - 13.3.3.1 Company Overview
    - 13.3.3.2 Product Portfolio
    - 13.3.3.3 Financials
    - 13.3.3.4 SWOT Analysis
  - 13.3.4Bristol-Myers Squibb Company
    - 13.3.4.1 Company Overview
    - 13.3.4.2 Product Portfolio
    - 13.3.4.3 Financials
    - 13.3.4.4 SWOT Analysis
  - 13.3.5F. Hoffmann-La Roche AG (Roche Holding AG)
    - 13.3.5.1 Company Overview
    - 13.3.5.2 Product Portfolio
    - 13.3.5.3 SWOT Analysis
  - 13.3.6Gilead Sciences Inc.
    - 13.3.6.1 Company Overview
    - 13.3.6.2 Product Portfolio
    - 13.3.6.3 Financials
    - 13.3.6.4 SWOT Analysis
  - 13.3.7GlaxoSmithKline Plc
    - 13.3.7.1 Company Overview
    - 13.3.7.2 Product Portfolio
    - 13.3.7.3 Financials
    - 13.3.7.4 SWOT Analysis
  - 13.3.8Johnson & Johnson
    - 13.3.8.1 Company Overview
    - 13.3.8.2 Product Portfolio
    - 13.3.8.3 Financials

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 13.3.8.4 SWOT Analysis
- 13.3.9 Merck & Co. Inc.
  - 13.3.9.1 Company Overview
  - 13.3.9.2 Product Portfolio
  - 13.3.9.3 Financials
  - 13.3.9.4 SWOT Analysis
- 13.3.10 Pfizer Inc.
  - 13.3.10.1 Company Overview
  - 13.3.10.2 Product Portfolio
  - 13.3.10.3 Financials
  - 13.3.10.4 SWOT Analysis
- 13.3.11 Sanofi S.A.
  - 13.3.11.1 Company Overview
  - 13.3.11.2 Product Portfolio
  - 13.3.11.3 Financials
  - 13.3.11.4 SWOT Analysis

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

## Hospital Infection Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Market Report | 2023-10-15 | 142 pages | IMARC Group

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

### ORDER FORM:

Select license	License	Price
	Electronic (PDF) Single User	\$2499.00
	Five User Licence	\$3499.00
	Enterprisewide License	\$4499.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-10"/>
		Signature	

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com





**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)  
[www.scotts-international.com](http://www.scotts-international.com)